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MicroRNAshaveemergedasimportantregulatorsofcellproliferation,development,cancerformation,stressresponses,celldeath,
and other physiological conditions in the past decade. On the other hand, head and neck cancer is one of the top ten most
common cancers worldwide. Recent advances in microRNAs have revealed their prominent role in regulating gene expression and
provided new aspects of applications in diagnosis, prognosis, and therapeutic strategies in head and neck squamous carcinoma.
In the present paper, we focus on microRNAs showing signiﬁcant diﬀerences between normal and tumor cells or between cells
with diﬀerential ability of metastasis. We also emphasize speciﬁc microRNAs that could modulate tumor cell properties, such as
apoptosis, metastasis, and proliferation. These microRNAs possess the potential to be applied on clinical therapy in the future.
1.Introduction
Head and neck squamous cell carcinomas (HNSCCs)
account for approximately 10,000 emerging patients in the
USA per year. In the past 5 years, new subjects for HNSCC
in the USA increased approximately 25%, while the total
initiated cancer cases only increased about 5% during the
same period [1–6]. In Taiwan, HNSCC has been one of
the 10 leading causes of cancer deaths in the past decades.
The mortality rate also increased signiﬁcantly, from 4.25
per 100,000 in 1995 to 9.6 per 100000 in 2006, a 2.26-fold
increase in one decade [7]. Several risk factors for HNSCC
have been reported, such as oropharynx-related problems,
betelquidchewing,cigarette,andalcoholabuse[7–11].Betel
quid chewing is widespread in Taiwan, especially among
the indigenous people and blue-collar workers, with a total
estimated two million habitual users (10% of population)
[12]. Betel quid chewing has also been associated with
cancer prognosis in a dose- and time-dependent fashion. In
a study of 378 HNSCCC patients, the 5-year survival rate
of betel quid chewers was signiﬁcantly lower than that of
nonchewers[13].Arecanutextract(ANE)ishighlycytotoxic
and genotoxic to cultured human oral mucosal epithelial
cells and ﬁbroblasts. Exposure of human keratinocytes to2 Journal of Oncology
ANE results in apoptosis, generation of reactive oxygen
species, genetic damage, and micronuclei formation [14].
The same study has found that a 24-hour treatment with
ANE induced mutations at the hypoxanthine phosphoribo-
syltransferase (HPRT) locus in human keratinocytes [14].
Increased intracellular levels of reactive oxygen species and
8-hydroxyguanosine in cells exposed to ANE have been also
reported [14]. Arecoline has been shown to induce structural
chromosomal aberration, sister chromatid exchange, and
micronuclei formation in diﬀerent cell types [15, 16].
Moreover, it has been shown that arecoline induced a
signiﬁcant elevation of cyclin-dependent kinase inhibitor 1
(p21/waf1) and a decline of cell division control protein 2
(cdc2) and cyclin B1 in gingival keratinocytes [17]. Despite
the recent development of molecular-targeted therapeutics
and other updated treatment regimens, HNSCC remains
diﬃcult to manage. Most patients with advanced HNSCC
die from locoregional progression, with local recurrence
rate up to 40% even after multimodality treatment [8, 18,
19], indicating that a better understanding of molecular
pathogenesis for this disease is urgently needed.
Several molecular pathways are involved in the process
of HNSCC carcinogenesis. For instance, high expression of
cyclin A and cyclin D1 raises the carcinogenicity in oral
cancers. Besides, p27Kip1, an inhibitor of cyclin-dependent
kinases, has been reported as a prediction marker for
survival rate [20–22]. As a tumor suppressor, p53 function
is suppressed when overexpresing murine double minute
g e n e2( M D M 2 )i no r a lc a n c e rc e l l s[ 23]. Moreover,
many apoptosis-related, adhesion molecular-related, and
inﬂammation-related proteins, such as activating protein-1
(AP1), survivin, Ras and Ras-related C3 botulinum toxin
substrate 1 (Rac-1), cyclooxygenase-2 (COX-2), epidermal
growth factor receptor (EGFR), human epidermal growth
factor receptor 2 (Her-2), signal transducer, and activator of
transcription 1 (STAT-1) as well as caspase-1, play important
roles in HNSCC carcinogenesis [24–28].
MicroRNAs(miRNAs),approximately18–25nucleotides
in length, are a group of endogenous small and noncoding
RNAs. Since its ﬁrst discovery in 1993, the biological
function and biogenesis of miRNAs became popular topics
for biomedical researches. They are transcribed to form a
primary miRNA via RNA polymerase II. Primary miRNA
is processed into precursor miRNA (pre-miRNA) by Drosha
and DRG 8 and is then exported from nucleus to cytoplasm
through exportin 5. The pre-miRNA is modiﬁed by Dicer
and the matured miRNA forms. There are about 1000
diﬀerent miRNAs which have been discovered and estimated
in human genome [29]. MiRNAs play a critical role in
the regulation of gene expression. As expected, miRNAs
expression is highly correlated with human diseases, such as
cancer and aging [30]. MiRNAs donot only act as oncogenes
but also as tumor suppressors, which further implicates their
role as therapeutic targets [31].
The aim of this paper is to highlight miRNA as a novel
modulator in HNSCC. Considering the rising importance
of miRNA and increasing cases of HNSCC, we hope
this paper would shed some light on cancer therapy and
provoke ideas for new research in order to ﬁnd out more
details about and mechanisms beneﬁcial for therapeutics of
HNSCC.
2. MiRNA-Related Ageing andCancers
Epigenetics of ageing is an emerging ﬁeld involving the
mechanismsthataﬀectgeneexpressionsotherthaninherited
DNA sequences regulating the tumorigenesis in multi-
ple cancers. Factors such as DNA methylation, histone
modiﬁcation, chromatin remodeling, the polycomb protein
groups, and noncoding RNAs can all contribute to the
broad variety of phenotypes of ageing. The category of
small noncoding regulatory RNAs includes miRNAs, small
interfering RNAs (siRNAs), PIWI-interacting RNAs (piR-
NAs), small nucleolar RNAs (snoRNAs), and small nuclear
RNAs (snRNAs). Among these, we focused on a group
of microRNAs and their impact on facets of organismal
aging as well as cellular senescence. Most miRNA-mediated
regulation occurs at the posttranslational level, primarily
through its near-perfect or partial complementary ﬁt against
the coding region or 3
  untranslated region (UTR) of
target mRNA, leading to translational repression and/or
degradation, therefore, the regulation of gene expression.
In rare cases, they may also promote translation [32,
33].
The roles of miRNAs in cancers have been extensively
investigated in the past few years. The relevance of miRNAs
incancerwassuggestedbythechangesinexpressionpatterns
[34]a n dr e c u r r e n ta m p l i ﬁ c a t i o na sw e l la sd e l e t i o no f
miRNA genes in cancers. Calin et al. were the ﬁrst to
reportthesignatureof13microRNAscapableofdistinguish-
ing between indolent and aggressive chronic lymphocytic
leukemia (CLL) [35]. Since then, several miRNAs have
emerged as candidate component of oncogenes and tumor-
suppressor networks. The miRNAs aberrant expressions in
cancers are summarized in Table 1.
IthasbeendemonstratedthatmiRNAscanfunctionboth
as oncogenes and tumor suppressors in the development
of cancers. Recently, the connection of miRNA biogenesis
and tumor suppressor networks was elucidated. p53 is a
well-known tumor suppressor regulating diverse physical
responses to many cancer-related stress signals, which could
be translated to aﬀect cell proliferation, cell death, DNA
repair, and angiogenesis. Eﬀorts have unraveled the linkage
between p53 and several miRNAs. Xi et al. found that miR-
30a-5p, miR-181b, miR-372, let-7g, miR-26a, let-7b, miR-
296, and miR30a-3p were upregulated by wt-p53, whereas
miR-15b, miR-27a, miR200c, miR-191, miR-30c, miR-25,
miR-107, miR-339, miR-125, miR-27b, miR-23a, and miR-
10a were downregulated by wt-p53 in human colon carci-
nomacelllines[36],suggestingthatp53playsaroleinawide
range of miRNA expression. Another study analyzing 470
miRNAs found that 12 miRNAs were signiﬁcantly aﬀected
by p53 [37]. Recent evidences indicated that miRNAs are
directly regulated by p53. He et al. reported that miR-
34a, miR-34b, and miR-34c reﬂected p53 status and the
expression of these miRNAs was induced by DNA damage
and oncogenic stress in a p53-dependent manner leading
to apoptosis or cellular senescence [38]. These ﬁndingsJournal of Oncology 3
Table 1: MicroRNA aberrant expression in cancer.
Tumor type Upregulated miRNA Downregulated miRNA References
Glioblastoma
miR-21
miR-7 [121–125] miR-221
miR-222
Lung
let7-5a miR-1, let-7 family, miR-7,
[121, 126–130]
miR-17-92 cluster, miR-18b, miR-15a/miR-16, miR-29
miR-20a, miR-21, miR-34c, family, miR-32, miR-137,
miR-106a, miR-155, miR-182, miR-342
miR-328 miR-145
Breast
miR-10b, miR-21, miR-22, let-7, miR-7, miR-9-1,
[34, 131–133]
miR-27a, miR-155, miR-210, miR-17/miR-20, miR-31,
miR-221, miR-222, miR-328, miR-125a, miR-125b,
miR-373, miR-520c
miR-146, miR-200 family,
miR-205, miR-206,
miR-335
Hepatocellular carcinoma
miR-17-92 cluster, miR-21, miR-1, miR-34a
[134–140] miR-143, miR-221 miR-101, miR-122a
miR-224 miR-125b
Gastric cancer miR-21, miR-27a, miR-130b miR-101, miR-143, miR-145 [141–143]
Colorectal cancer miR-17-92 cluster, miR-21
miR-34a, miR-34b/c,
miR-127, miR-143, [144–149]
miR-145, miR-342
Prostate cancer miR-221, miR-222
miR-15a-miR-16-1 cluster,
[144, 150–153] miR-101, miR-127,
miR-449a
Lymphoma miR-17-92 cluster, miR-155 miR-143, miR-145 [154–156]
CLL miR-21, miR-155
miR-15, miR-16, miR-29b,
[35, 156–160] miR-29c, miR-34a,
miR-143, miR-145,miR-181b,
miR-223
CLL: chronic lymphocytic lymphoma.
elucidated that miRNAs play crucial roles in the p53 tumor
suppressor pathways.
3.MiRNAs TargetMolecular
PathwaysinHNSCC
3.1. MiRNA Expression Proﬁles. MiRNA proﬁling in head
and neck cancer has been reviewed by Liu et al. and
Tran et al. [39, 40]. Recently reported HNSCC-related
miRNAsexpressionproﬁlingissummarizedinTable 2.Some
miRNAs show consistently altered expressions in diﬀerent
studies. For example, the upregulated expression of miR-
21, miR-31, miR-18, and miR-221 has been reported in at
least 2 diﬀerent study series. Similarly, the expression of
miR-133a, miR-133b, miR-125a, miR-138, miR-139, miR-
200c, miR-26b, miR-302b, miR-302c, miR-342, miR-371,
and miR-373, is consistently reported to be downregulated
in HNSCC. Exception for certain miRNAs, all published
miRNA proﬁling shared little in common. This may be due
to various types of sample applied. Generally, the analysis of
upregulation and downregulation of miRNA proﬁles were of
consistence. However, there still were considerable variations
between diﬀerent researches. These discrepancies may be
due to diﬀerent sampling locations/cell lines (miR-9, 16,
23b, 29c, 31, 34b, 138, 221, 375, and 449), methods for
performing the assays (miR-16, 29c, and 340), and scope
of the microarrays (miR-16, 23b, 29c, 221, 340, 375, and
449). For example, the same miRNAs possessed opposite
proﬁles between the squamous cell carcinomas and the
nasopharyngeal carcinomas/pleomorphic adenomas. These
manifestations might be contributed from diﬀerent cell
diﬀerentiations that were modulated by the same miRNAs
under various circumstances. Sampling technique of the
tumor tissue also inﬂuenced the proportion of tumor cells
to nontumor cells that may interfere with the sensitivity of
real-time PCR and microarray analysis.
3.2. MiRNAs Aﬀect Apoptosis or Metastasis. There are sev-
eral reasons indicating that miRNAs play several roles in
human cancer, one of which is miRNAs-mediated cell death.4 Journal of Oncology
Table 2: Antecedent studies identiﬁed microRNA expression level change in head and neck cancer.
miRNA Up-regulated Down-regulated Study groups/methods References
let7i; 15a; 15b; 17a; 18; 18a; 18b;
pre 21; 21; 21-17p; 24-1p; 98;
99b; 104; 126; 130b; 137; 140;
142-3p; 146; 146b; 151; 152; 155;
181b; 181d; 184; 188; 192; 193b;
199b-2p; pre-205; 213; 301; 325;
333; 337; 338; 374; 455; 491
v [61, 102, 113–
115, 161–167]
let-a family; let-7 family; let7a;
10b; 20b; 23 family; 27 family;
30; 34 family; 34c; 93-7p; 99a;
100; 107; 125; 125a; 127; 144;
154; 195; 200 family; 200a;
291-3p; 368; 370; 378; 422
family; 494
v
[61, 102, 113,
114, 119, 162,
164–168]
9 v 13 NPC/real time-PCR [162]
v 18 OC cell
lines/real-time-PCR [164]
16 v 9 HNSCC cell
lines/Microarray [113]
v 31 NPC/real time-PCR [166]
17 v 13 NPC/real time-PCR [162]
v 31 NPC/real time-PCR [166]
23b v 104 HNSCC/Microarray and
real time-PCR [102]
v 5 SCC/real time-PCR [165]
29c v 4 HNSCC/Microarray [114]
v 31 NPC/real time-PCR [166]
31 v 18 OC cell lines/real time-PCR [164]
v 13 NPC/real time-PCR [162]
34b
v 5 SCC/real time-PCR [165]
v
13 NPC/real
time-PCR [162, 166]
31 NPC/real
time-PCR
138 v 13 NPC/real time-PCR [162]
v 4 OSCC/real time-PCR [61]
221
v
99 HNSCC and 14
normal/Microarray
and real time-PCR [115, 165]
5 SCC/real time-PCR
v 31 NPC/real time-PCR [166]
340 v 18 OC cell lines/real time-PCR [164]
v 9 HNSCC cell
lines/Microarray [113]
375
v 169 HNSCC/real time-PCR [161]
v
99 HNSCC and 14
normal/Microarray
and real time-PCR [115, 167]
16 pleomorphic
adenoma/Microarray
and real time-PCR
449 v
16 pleomorphic
adenoma/Microarray and real
time-PCR
[167]
v 9 HNSCC cell
lines/Microarray [113]
MiRNA: microRNA; NPC: nasopharyngeal carcinoma; OC: oral cancer; HNSCC: head and neck squamous cell carcinoma; SCC: squamous cell carcinoma.Journal of Oncology 5
Apoptosis is the active process of programmed cell death.
It happens in multicellular organisms and is controlled by
an intracellular program of gene expression. In humans, the
balance between proliferation and apoptosis is important
and essential for homeostasis maintenance. Tumorigenicity
would be relatively easy to take place when this homeostasis
collapses. MiRNAs mediate tumorigenicity by directly tar-
geting antiapoptotic genes expression or proapoptosis genes
expression.
Metastasis, on the other hand, is another speciﬁc prop-
erty of cancer cells. MiRNAs directly inﬂuence metastasis
and have great impact on prognosis in clinical evaluation.
Manystudies to be discussed below in this paper showed that
miRNAsinhibitionoroverexpressionaﬀectedbothapoptosis
and metastasis. However, it is diﬃcult to tell if the results
of migration or invasion were impacted by their eﬀects on
a p o p t o s i sd e s p i t et h a ts o m em i R N A sh a v eb e e np r o v e dt o
directly target genes involved in metastatic capability. Table 3
lists all miRNAs discussed below.
3.2.1. Potential Tumor Suppressors. Several miRNAs are
f o u n dt oa c ta st u m o rs u p p r e s s o r s .H o n ge ta l . reported that
inhibition of miR-296 expression could promote esophageal
squamous cell carcinoma apoptosis. MiR-296 could up-
regulate Bcl-2-associated X protein (Bax) expression, down-
regulate B-cell lymphoma 1 protein (Bcl) expression, sup-
press cyclin D1 and p27 expression, and promote the
chemotherapeutic sensitivity [41]. Long et al. showed that
up-regulation of let-7a promotes laryngeal cancer cell dys-
function by modulating proliferation, inhibiting metastasis,
and inducing apoptosis [42]. Comparing to normal human
laryngeal cells or nondiﬀerentiated cells, let-7a miRNA
expression level was highly suppressed. Furthermore, in the
same study, let-7a aﬀected RAS and c-Myc expression in
protein level, thus mediated cell apoptotic genes and onco-
genes expression. Reduction of miR-138, on the other hand,
was found in highly metastatic cells. Enforced expression of
miR-138 could mitigate invasion, lead to cell cycle arrest,
and induce cell apoptosis [43]. However, it is hard to tell
if miR-138 does aﬀect the ability of invasion or it is simply
impacted by raising the percentage of apoptosis. Recently,
the same group further demonstrated the role of miR-
138 in metastasis. They showed that miR-138 modulated
migration and invasion through targeting Ras homolog gene
family, member C (RhoC) and Rho-associated, coiled-coil
containing protein kinase 2 (ROCK2). Inhibition of miR-138
caused elongated cell morphology, increased cell stress ﬁber
generation, and enhanced cell migration as well as invasion
[44]. Other miRNAs such as miR-204 and miR-34c also
inhibit invasion. Leeetal.hadshownthat miR-204 is a newly
targetinggenewhichisasuppressorofmetastasisinheadand
neck cancer. Enhancement of miR-204 expression directly
led to the reduction of proliferation, invasion, and migration
in HNSCC cell lines and mitigated experimental lung organ
metastasis in animal study [45]. They also demonstrated that
overexpressionofmiR-204isassociatedwithearlyrecurrence
in those HNSCCs expressing EGFR-pathway signature. MiR-
34c, on the contrary, functioned as tumor suppressor that
targeted 3
 UTR of c-Met and inhibited cell growth and
invasion [46]. This suggested that downregulation of miR-
34c may contribute to malignancy in human laryngeal
carcinoma through a mechanism involving targeting of c-
Met.
3.2.2.ApoptoticAntagonistsorMetastasisStimulators. Onthe
contrary, several miRNAs act as a mediator of apoptotic
antagonist or promote metastasis. Zhang et al. demonstrated
thatmiR-141couldinﬂuencecellcycle,apoptoticphenotype,
cell migration and invasion by regulating Bromodomain-
containing protein 3 (BRD3), Ubiquitin-associated pro-
tein 1 (UBAP1), c-Jun N-terminal kinases (JNK), ser-
ine/threonine protein kinase (Akt/PKB), and phosphatase
and tensin homolog (PTEN) signaling transduction path-
ways in nasopharyngeal carcinoma. The study showed a
highly positive correlation between miR-141 and c-Myc
expression and an opposite expression pattern between miR-
141 and short palate, lung, and nasal epithelium clone 1
(SPLUNC1) [47]. Lee et al. published that miR-373 plays
a pivotal role in regulating large tumor suppressor that
homolog 2 (LATS2), a tumor suppressor has been implicated
in modulating cell cycle and inducing apoptosis [48, 49].
MiR-373 is therefore considered to be a proliferation stimu-
lator and an apoptosis inhibitor in human esophageal cancer
[50]. MiR-21-attenuated cancer cells provoke apoptosis via
modulating anti-apoptotic proteins. MiR-21 is found to
targetprogrammedcelldeath4gene(PDCD4),tropomyosin
1 (TPM1), and PTEN to inhibit apoptosis, promote trans-
formation, and enhance colony formation [7, 51–53]. MiR-
21 inhibitor displayed a statistically signiﬁcant enhance in
cytochrome c release and apoptotic expression, indicating
that mir-21 is an unequivocal oncogenic miRNA in HNSCC.
Recently, we explored that CD44, aldehyde dehydrogenase
1 (ALDH1), and phosphorylated STAT3 (p-STAT3) were
higher in high-grade HNSCCs and that triple positivity
for CD44/ALDH1/p-STAT3 indicated a worse prognosis
for HNSCC patients [54]. In this study, CD44+ALDH1+
cells isolated from seven HNSCC patients showed greater
tumorigenicity, radioresistance, and high expression of
stemness (Bmi-1/Oct-4/Nanog) and epithelial-mesenchymal
transitional (Snail/Twist) genes as p-STAT3 level increased.
Recent studies showed that mir-21 is a key determinant
in IL-11/STAT3 anti-apoptotic signaling pathway [55]a n d
STAT3 activation of miR-21 and miR-181b-1 via PTEN and
cylindromatosis (CYLD) are part of the epigenetic switch
linking inﬂammation to cancer [56].
Additionally, a correlation was found between miR-211
expression level and the cancer metastasis in human oral
carcinoma. MiR-211 expression is higher in tumors with
vascular invasion and is correlated with poor prognosis.
Enforced miR-211 expression intensively increased migra-
tion,colonyformation,andtumorigenicityinoralsquamous
cell carcinoma (OSCC) cell line [57]. miR-222, on the other
hand,regulatesmetalloproteinase1(MMP1)andmanganese
superoxide dismutase 2 (SOD2) expression by targeting their
3
 UTR [58]. The reasons of miR-222 inhibited invasion
was through both cis- and trans-regulatory mechanisms
[58].6 Journal of Oncology
Table 3: miRNAs involved in tumorigenesis of HNSCC.
microRNA Tumor sites or cell lines Physiological eﬀects Potential target(s) Reference(s)
let-7a Laryngeal squamous cancer tissues;
Hep-2 cells
Let-7a mimic transfection suppressed
proliferation and induced apoptosis in
Hep-2 cells
RAS and c-MYC [42]
miR-10b
Human esophageal cancer cell lines
(KYSE30, KYSE70, KYSE140,
KYSE150, KYSE410, KYSE450,
KYSE510, and EC9706)
Ectopic expression of miR-10b
promoted migration and invasion KLF4 [169]
miR-15a HNSCC SQ20B cell line miR-15a inhibition promoted DNA
synthesis Cyclin E [60]
miR-21
Primary tongue carcinoma and
primary esophageal squamous cell
carcinomas; human tongue cancer cell
lines (SCC-15 and CAL27) and
esophageal squamous cell carcinoma
cell lines (TE6, TE8, TE10, TE11,
TE12, and TE14)
miR-21 inhibition inhibited cell
growth and promoted apoptosis
TPM1, PTEN, and
PDCD4 [51–53]
miR-31 OSCC SAS cell line
Ectopic expression increased the
oncogenic potential of HNSCC cells
under normoxia conditions
FIH [73]
miR-100 UPCI:SCC029 cells Transfection of miR-100 mimics
inhibited proliferation
D1, EGR2,
MMP13, and
FGFR3
[62]
miR-125b UPCI:SCC029 cells Transfection of miR-125b mimics
inhibited proliferation
KLF13, CXCL11,
and FOXA1 [62]
miR-138
Six paired HNSCC cell lines
(UM1/UM2, 1386Tu/1386Ln and
686Tu/686Ln with diﬀerent migration
or invasion ability
Ectopic expression caused cell cycle
arrest, apoptosis, and suppressed
invasion
RhoC and ROCK2 [43, 44]
miR-141
5–8F cell line (an NPC cell line)
knockdowned c-MYC or re-expressed
SPLUNC1
miR-141 inhibition decreased
migration, inhibited invasion, and
slightly enhanced apoptosis
BRD3, UBAP1,
and PTEN [47]
miR-184 TSCC Cal27, HN21B, and HN96 cell
lines
miR-184 inhibition resulted in
proliferation inhibition and apoptosis c-Myc [61]
miR-196 Esophageal cancer tissues
Downregulation of miR-196 inhibited
growth and conferred drug-sensitivity
of esophageal cancer cells
N.D. [41]
miR-200c 5 primary HNSCC CSC
Upregulation of miR-200c inhibited
the cancer stem cell-like properties of
ALDH1+CD44+ HNSCC
Bmi-1 To be published
miR-203 HNSCC JHU-012 cells miR-203 induced cell cycle arrest and
apoptosis upon UVC irradiation DeltaNp63 [64]
miR-204
HNSCC cell lines (SCC25, SCC35,
SCC58, SCC61, SCC135, SCC151,
SQ20B, SQ38, and JSQ3)
miR-204 mimics repressed
proliferation, invasion, and migration N.D. [45]
miR-210 Pancreatic cancer cell line SU86.86 and
Fadu cells
Ectopic expression repressed xenograft
tumor growth
HOXA1, HOXA9,
and FGFRL1 [70]
miR-211 OSCC SAS cell line
Enforced expression of miR-211
enhanced migration, invasion, and
colony formation
N.D. [57]
miR-222 HNSCC UM1/UM2 cell lines Transfection of miR-222 mimics
inhibited invasion MMP1 and SOD2 [58]
miR-373
The esophageal cancer cell lines
(CE48T, CE146T, KYSE70, KYSE150,
KYSE170, KYSE5, 10KYSE50, and
CE81T)
miR-373 enhances cell proliferation in
esophageal cancer cell lines LATS2 [50]
miR-503 UMSCC10B cell line Transfection of miR-503 decreased S
phase and cell growth Cyclin D1 [59]
N.D: not determined.
Abbreviations: HNSCC: head and neck squamous cell carcinoma; OSCC: oral squamous cell carcinoma. NPC: nasopharyngeal carcinoma; TSCC: tongue
squamous cell carcinoma; CSC: cancer stem cell.Journal of Oncology 7
3.3. Proliferation. The capability of proliferation is a vital
element of cancer cells. MiRNAs could target and regu-
late genes involved in cell cycle control or proliferation
stimulation, and therefore, play a key role in modulating
the phenotypes of cancer cells. Despite the promotion of
metastatic ability of miR-211, forced expression of miR-211
accompaniedwithenhancedproliferation[57].However,the
underlying mechanism is still unknown. On the other hand,
cyclin D1 is frequently overexpressed in cancer cells. Jiang et
al.focusedoncyclinD1andtriedtoidentifyspeciﬁcmiRNAs
targetingitsmRNA.TheyfoundthatmiR-503couldnotonly
suppress luciferase activity in reporter assay but also reduce
mRNA and the protein level of cyclin D1 in human HNSCC
cell line, UMSCC10B [59]. Despite the fact that miR-503
could alter S-phase and cause inhibition of cell proliferation,
the physiological signiﬁcance of miR-503 in HNSCC is still
lacking. Cyclin E, another cell cycle regulator, is regulated by
miR-15a. Anti-miR-15a, therefore, promoted DNA synthesis
[60]. MiR-184 was discovered by comparing 4 tongue
carcinomas and paired normal tissues through TaqMan
miRNA assays. MiR-184 inhibition leads to proliferation
inhibition, c-Myc reduction, and apoptosis in three SCC
cell lines [61]. However, the authors did not explain the
reduction of c-Myc nor if apoptosis was direct or indirect
consequence of miR-184 inhibition. Further examination
is required to understand the downstream targets of miR-
184. Due to unknown mechanism, the plasma level of miR-
184 highly was correlated with tumor status and seems
to be a potential biomarker for SCC. MiR-100 and miR-
125b are downregulated in OSCC. Exogenous expression
of these two miRNAs could reduce cell proliferation [62].
However, the study only provided potential targets aﬀected
by miR-100 and miR-125b mimicking transfection. The
direct targets are still undetermined. While Ubiquitin-like
protein SUMO-1 conjugating enzyme (Ubc9) is upregulated
in breast, head and neck, and lung cancer specimens, it
could also be regulated by miR-30e [63]. In HeLa cells,
ectopicexpressionofmiR-30ecouldnegativelyregulateUbc9
expression and suppress cell growth. Whether miR-30e has
the same eﬀects in HNSCC cells still needs to be veriﬁed.
Additionally, in response to genotoxic stress, altered miRNAs
might be associated with stress responses and be responsible
for drug resistance of tumor cells. In HNSCC, for instance,
miR-203 targets DeltaNp63 in response to genotoxic stress
[64]. Under ultraviolet light c (UVC) exposure, miR-203
was upregulated and correlated with DeltaNp63 decrement.
MiR-203, therefore, can regulate DeltaNp63 expression and
control cell survival upon genotoxic stress.
4. The Relationship betweenMiRNAs,
Hypoxia,andEpithelial-Mesenchymal
Transitionand Cancer
Poor prognosis of HNSCC patients was found to related
to hypoxia [65–67] and epithelial-mesenchymal transition
(EMT) [68]. Hypoxia is a critical and major feature of cancer
microenvironment. It could aﬀect and determine many
vital responses of tumor cells and account for protection
towardradiotherapyandchemotherapy.YangandWu.found
that the hypoxic response is mainly mediated by hypoxia
inducible factor-1 (HIF-1) that promotes EMT through
direct regulation of a basic-helix-loop-helix transcription
factor (TWIST) expression. They concluded that coexpres-
sion of HIF-1α, TWIST, and Snail could be used as a
prognosticmarkerinHNSCCpatients[69].SeveralmiRNAs,
such as miR-210, are found to be hypoxia inducible. Upon
hypoxia, miR-210 expression is induced. The majority of
target candidates of miR-210 are genes expressed under
normoxia. When miR-210-overexpressed cell lines were
xenotransplanted into the mice, the tumor volumes were
lower than the parental control. It suggests the fact that
miR-210 may participate in tumor initiation in response
to hypoxia [70] and is a prognostic indicator in HNSCC
[71]. Two other miRNAs are also associated with hypoxia.
MiR-31 ablates expression of HIF and regulates hypoxia
responses [72, 73]. Also, in hypoxia, the expression of miR-
98 is elevated, and it targets high-mobility group AT-hook
2 (HMGA2), which sensitizes HNSCC to topoisomerase II
inhibitor, doxorubicin [74].
Epithelial-mesenchymal transition is a process by which
epithelial cells lose their polarity and are converted to a
mesenchymal phenotype, which has been recently regarded
as the critical event to induce morphogenetic changes during
embryonic development, organ ﬁbrosis, and tumor metasta-
sis [75–78]. Phenotypic changes of EMT include the down-
regulation of epithelial markers (e.g., E-cadherin, desmo-
plakin and plakoglobin) and upregulation of mesenchymal
markers (e.g., vimentin, ﬁbronectin, and α-smooth muscle
actin) [75–78]. Transcriptional factors including Snail, Slug,
TWIST, Zeb1, Zeb2, and E47 were shown to induce EMT
through the repression of E-cadherin, and they are perceived
as EMT regulators [79–84]. Major causes of HNSCC-related
deaths are cervical node and distant metastasis. EMT was
demonstrated to be the major mechanism responsible for
mediating invasiveness and metastasis of late-stage can-
cers. Dr. Yang and his colleagues explored that Nibrin
(NBS1) overexpression upregulated the expression of an
EMT regulator Snail and its downstream target matrix
metalloproteinase-2 [85]. Recent evidence suggests that
depletion of the population of cancer stem cells (CSCs)
decreases cancer recurrence and metastasis [86]. Prince et
al. further demonstrated that the puriﬁed CD44+ population
of HNSCC cells possesses the properties of cancer stem
cells [87]. Subpopulation of CD44 positive cells showed
chemoresistant genes ATP-binding cassette subfamily B
member 1 (ABCB1), ATP-binding cassette sub-family G
member 2 (ABCG2), cytochrome P4502C8 (CYP2C8), and
telomerase reverse transcriptase (TERT) [88]. Our previous
work showed that ALDH1+-lineage plays a crucial role in
maintaining self-renewal and cancer stem-like properties
in HNSCC cells [89]. ALDH1+-lineage cells are shown to
have EMT shifting and endogenously co-expressed snail.
Furthermore, the knockdown of snail expression signiﬁ-
cantly decreased the expression of ALDH1, inhibited cancer
stem-like properties, and blocked the tumorigenic abilities
of CD44+CD24−ALDH1+cells [89]. We also explored the
enriched OC-SLC which possesses the characteristics of both8 Journal of Oncology
Table 4: Potential miRNAs for prognosis in HNSCC.
Potential microRNA as prognostic marker Type of abnormal expression Type of samples Reference(s)
miR-21
OSCC miR-181b Overexpression [116]
miR-345
Combined Let-7d and miR-205 Underexpression HNSCC [102]
miR-21 Overexpression TSCC [51]
miR-210 Overexpression HNSCC [71]
miR-211 Overexpression OSCC [57]
miR-296 Overexpression ESCC [41]
Combined miR-221 and miR-375
Overexpression of miR-221
HNSCC
[115]
Underexpression of miR-375
OSCC: oral squamous carcinoma cell; HNSCC: head and neck squamous carcinoma cells; TSCC: tongue squamous carcinoma cell; ESCC: esophageal
squamous carcinoma cells.
stem cells and malignant tumors [90]. Additionally, expres-
sion of stemness markers (Nanog/Oct-4/CD133) contradicts
the survival prognosis of OSCC patients [90]. Our data
showed that ALDH1+ cells from HNSCC displayed higher
levels of Bmi-1, and we further found that Bmi-1-silenced
ALDH1+ cells showed increased sensitivity to radiotherapy
and lower abilities for tumor invasion, colony formation,
and self-renewal. Survival analysis further demonstrated that
the mean survival rate of mice with ALDH1+ tumors under
radiation treatment was signiﬁcantly improved by knock-
down of Bmi-1 [91]. More recently, Song et al. showed
that Bmi-1 could directly promote EMT and malignancy
in nasopharyngeal carcinoma by regulating snail [92]. Fur-
thermore, there is growing evidence of the crosstalk and
correlation between stemness pathways, tumor progression,
and metastasis. The functional and mechanical signiﬁcance
of the overexpressed biomolecular pathway in HNSCC-CSC,
h o w e v e r ,i ss t i l lb l u r r e da n dn e e d st ob ec l a r i ﬁ e d .
Several miRNAs were reported to be associated with
CSC in hepatocellular carcinoma, pancreatic cancer, breast
cancer, and brain tumors [93–96]. It has been reported that
overexpression of miR34 impairs the self-renewal properties
o fC S Ci s o l a t e df r o mb r a i nt u m o r sa n dp a n c r e a t i cc a n c e r
[94, 97]. Tumorigenicity of breast CSC is also suppressed
by ectopic let-7, miR200c, and miR30 expression [98–100].
MiR-181 family members are highly expressed in liver CSC,
and silencing of miR-181 may eradicate liver cancer [93].
Therefore, it is of interest to ask whether microRNA is
involved in regulating self-renewal and metastatic properties
in HNSCC or HNSCC-associated CSC. In HNSCC, multiple
miRNAs have been reported to be involved in HNSCC
pathogenesis. It has been found that expression of oncogenic
miR21 and miR184 promotes tumorigenicity in HNSCC
[51,61].Incontrast,ectopicexpressionoftumor-suppressive
miR98, miR-137, and miR-193a resulted in a loss of
cell growth of HNSCC. Recent clinicopathological ﬁndings
demonstrated that the down-regulation of miR-133a, miR-
133b, miR-205, and let-7d in HNSCC tumor tissues could be
utilized for predicting the prognosis of patients withHNSCC
[101, 102]. Our previous study also demonstrated that
oncogenic miR31 and miR221 upregulated HIF expression
and elevated tumorigenicity in HNSCC [57, 73].
MicroRNAs can act not only as oncogenes but also as
tumour suppressors [29, 30]. Therefore, it is plausible to
consider miRNAs as therapeutic targets in cancer cells [31].
MiR200c is a crucial modulator of EMT, tumourigenicity,
and metastasis [99, 103–105]. It has been reported that
miR200cisdown-regulatedandexhibitstumour-suppressive
properties in renal cell, prostate, breast, bladder, pancreatic,
and gastric cancers [106–110]. MiR200c is required for the
growth of mammary stem cells and self-renewal proper-
ties of breast CSC through the direct targeting of Bmi-
1[ 99]. Down-regulation of miR-200c promotes EMT of
breast cancer cells while overexpression of miR-200c induces
mesenchymal-epithelial transition [105, 111]. Notably, miR-
200c was reported to regulate pancreatic cancer cells, EMT,
and cancer stemness properties by targeting ZEB1/ZEB2,
Bmi-1, and Sox2 [112]. However, the role of miR200c
in regulating tumourigenicity and metastasis in HNSCC
or HNSCC-CSC has not been reported yet. Our recent
study showed that the expression of miR200c in the
regional metastatic lymph node of HNSCC tissues was
signiﬁcantly decreased, but Bmi-1 expression was increased
as compared to parental tumours (unpublished data).
Importantly, the site-directed mutagenesis with luciferase
reporter assay showed that miR200c is targeting 3nesis
with parental tumours (unpublished data). MiR200cs were
signiﬁcantly down-regulated while Bmi-1 was increased in
HNSCC-ALDH1+/CD44+ compared to the other subsets
of HNSCC cells. Notably, overexpressing miR200c further
down-regulated the protein expressions of ZEB1, snail,
and N-cadherin but up-regulated E-cadherin expression in
ALDH1+/CD44+ cells. Xenotransplanted study conﬁrmed
that overexpression of miR200c or knockdown of Bmi-1
eﬀectivelyinhibitedthelungmetastaticabilityandprolonged
the survival rate of ALDH1+/CD44+-transplanted mice.Journal of Oncology 9
5. Implicationsof MiRNAs as
BiomarkersinHNSCC
Traditional tumor suppressor or proto-oncogene has been
expended to the ﬁeld of miRNA due to fast progress
made in the past decade. Moreover, widespread technology
of microarray provides fast and large-scale screening for
potential targets in searching appropriate biomarkers. In
HNSCC,anumberofstudiespublishedpotentialbiomarkers
for cancer progression as well as prognosis. Even though
contradiction among these studies was found, a new era has
been opened up for therapeutic strategies in HNSCC. MiR-
21 is frequently overexpressed in HNSCC. It is the most
consistent miRNA found to be upregulated in many studies
discussing miRNA proﬁling in HNSCC [61, 102, 113–115].
Nevertheless, the universal upregulation of miR-21 does
not make it an appropriate marker for prognosis. Diﬀerent
conclusions were made in several studies. Cervigne et al.
indicated that miR-21 along with miR-181b, and miR-345
are markers for oral cancer progression [116] ,a n dL ie t
al. suggested miR-21 as an indicator for poor prognosis in
tongue SCC [51]. No signiﬁcant result was obtained in other
researches [71, 102]. A list of miRNA as potential prognostic
marker was provided in Table 4.
The signiﬁcance of polymorphisms at miRNA and
miRNA target sites in disease risk and prognosis has been
addressed and investigated [117, 118]. Because miRNAs reg-
ulate gene expression by binding to 3
 UTR sites, this binding
can be aﬀected by single nucleotide polymorphism (SNP)
resides within miRNA target sites. MiRNA or miRNA target
site polymorphism could abolish the existing target sites or
create illegitimate binding sites. These SNPs can therefore
aﬀect protein expression and lead to altered organismal
phenotypes. According to Saunders et al., a relatively low
polymorphism was found in functional region of miRNA
while many target sites are disrupted by high frequency
of SNPs. In HNSCC, let7-binding site polymorphism at
3
 UTR of V-Ki-ras2 Kirsten rat sarcoma viral oncogene
homolog (KRAS) (KRAS-LCS6) and sequence polymor-
phism in miR196A2 are both associated with reduced
survival in head and neck cancer [119, 120]. We recently
ﬁrst demonstrated that let-7a expression was signiﬁcantly
decreased but that Nanog/Oct4 expression was increased
in HNSCC tissues as compared to adjacent normal cells
(accepted and unpublished data). Expression of let-7a in
recurrent HNSCC tissue and in regional metastatic lymph
nodes of HNSCC patients was also signiﬁcantly decreased,
but Nanog/Oct4 expression was increased as compared to
the expression levels in the parental tumours. Consistently,
the stemness genes were signiﬁcantly up-regulated, and let-
7a was down-regulated in HNSCC-ALDH1+ cells relative
to HNSCC-ALDH1− cells. Furthermore, lentiviral-mediated
let-7a overexpression could signiﬁcantly inhibit the stem-
ness signature and the chemoresistant abilities of HNSCC-
ALDH1+ cells. Most importantly, overexpression of let-7 or
knockdown of Nanog in ALDH1+ cells eﬀectively blocked
tumour metastasis and signiﬁcantly prolonged survival time
inALDH1+-transplantedimmunocompromisedmice.Over-
all, restoration of let-7a in HNSCC and HNSCC-tumour
initiating cells may be a new approach for the therapeutic
treatment of HNSCC in the future.
6. Conclusions
Traditionally, the major theory of cancer is considered as
dysregulation of protein-coding tumor suppressor genes and
oncogenes. To date, the discovery of epigenetic regulation
providesnewexplanationstoandrevealsamorecomplicated
network of cancer formation. MiRNAs, a small group of
noncoding RNAs, draw more attention than ever and are
thought to be a new category of tumor suppressor or
oncogene. Accumulating knowledge in miRNA brings new
perspectives in understanding of cell transformation and
tumorigenicity. Nevertheless, growing numbers of HNSCC
cases need a breakthrough to improve the mortality rate of
HNSCC patients. Further studies are needed to understand
the mechanism of dysregulation of miRNA as well as their
targets.
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